Abstract
We analyzed the results of the LMB-89 protocol performed in seven centers in Venezuela in 96 children having B-cell non-Hodgkin lymphoma treated from 1995 to 2002. Mean age was 7.1 years with 71 (74%) been male. Eighty-two patients (85%) had diffuse small cell lymphoma Burkitt and Burkitt-like, and 14 (15%) had diffuse large B-cell lymphoma. Initial disease sites included the abdomen in 67%, peripheral nodes in 8%, and mediastinal in 4%. Treatment was directed to risk groups as described for LMB-89 protocol. Group A: seven patients (7%), group B: 80 patients (83%), and group C: nine patients (9%). Mean follow-up was 35 +/- 31 months. Complete remission (CR) occurred in 70 patients (73%); four patients (6%) had relapse during the first year and ten patients (10%) had progressive disease. Overall survival (OS) and event free survival (EFS) were 85 and 80% at 1 year, and 82 and 75% at 2 years, respectively. The EFS by therapeutic groups at 3 years was A: 100%; B: 76%, and C: 56%. neutropenia in 75%, thrombocytopenia in 63%, febrile neutropenia in 39%. Viral infections: hepatitis B in 20%, hepatitis C in 2%, and Herpes zoster in 3%. Tumor lysis syndrome (TLS) occurred in 9% during induction phase with a high mortality of 44% (urate...Continue Reading
References
Jan 1, 1977·British Journal of Cancer·R PetoP G Smith
Jan 1, 1976·Cancer·N WollnerM L Murphy
Jan 1, 1992·Medical and Pediatric Oncology·C PatteJ Lemerle
Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C PatteF Pein
Mar 1, 1990·Vaccine·O H Fay
Mar 10, 1983·The New England Journal of Medicine·J R AndersonD Hammond
Mar 1, 1995·Pediatric Hematology and Oncology·S BerberoğluI Ilhan
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R E HutchisonS B Murphy
May 9, 1996·The New England Journal of Medicine·J T SandlundW M Crist
Feb 23, 2000·Vaccine·J Tanaka
Feb 23, 2000·Vaccine·J Tanaka
Jul 6, 2000·Medical and Pediatric Oncology·A MeralU Günay
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L KobrinskyA T Meadows
May 23, 2001·Blood·C PatteUNKNOWN Société Française d'Oncologie Pédiatrique
Nov 6, 2001·Seminars in Hematology·C PatteD Sommelet
Nov 6, 2001·Seminars in Hematology·C H Pui
Citations
Aug 26, 2010·Journal of Pediatric Hematology/oncology·Tiraje Tülin CelkanInci Yildiz
Aug 4, 2012·Journal of Pediatric Hematology/oncology·Carolina CervioGuillermo L Chantada
Nov 6, 2012·Revista brasileira de hematologia e hemoterapia·Keyla Christy Christine Mendes Sampaio CunhaMarcos Borato Viana
Aug 22, 2007·Pediatric Hematology and Oncology·Ceyda KaradenizNur Aksakal
Apr 10, 2008·Leukemia & Lymphoma·Akira KikuchiMasahiro Tsuchida
Feb 27, 2008·Pediatric Blood & Cancer·Raul C Ribeiro, John T Sandlund
Aug 3, 2006·Pediatric Blood & Cancer·Scott C HowardUNKNOWN MISPHO Consortium Writing Committee
Jan 24, 2008·Pediatric Blood & Cancer·Mhamed HarifJean Lemerle
Feb 8, 2011·Pediatric Blood & Cancer·Maria Luisa MoletiAnna Maria Testi
Apr 20, 2010·Asia-Pacific Journal of Clinical Oncology·Naveed AhmadMuhammad S Akram
Apr 11, 2013·Pediatric Hematology and Oncology·Jennifer WorchBirgit Burkhardt
Oct 3, 2013·PloS One·Jared RowleyUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Feb 2, 2018·Pediatric Hematology and Oncology·Amol PatelSameer Bakhshi
Aug 29, 2018·Hematology·Felix Gaytan-MoralesUNKNOWN Mexican Association of Pediatric Oncology and Hematology (AMOHP)
Jan 25, 2019·Pediatric Blood & Cancer·Armando Peña-HernandezRaul C Ribeiro
Apr 19, 2019·Leukemia & Lymphoma·Maria Luisa MoletiSalma Al-Hadad
Aug 26, 2020·Blood Advances·Nmazuo W OzuahNader Kim El-Mallawany
Feb 12, 2019·British Journal of Haematology·Guillermo ChantadaScott C Howard
Mar 16, 2019·Science·Catherine G LamKathy Pritchard-Jones
Apr 11, 2018·BMJ Paediatrics Open·Hugo A MartijnSaskia Mostert
Aug 28, 2020·BMJ Case Reports·Sandra LangatSaskia Mostert